PB1953 QUALITY OF LIFE AND SYMPTOM BURDEN WITH FIRST AND SECOND GENERATION TYROSINE KINASE INHIBITORS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA
Conference paper > Summary Text
Authors: T. Toptas, H. Bostan, K. Kut, F. Pepedil Tanrikulu, Funda YILMAZ, I. Atagunduz, T. Tuglular
HemaSphere, , , International, Summary Text, vol 3, pp 887-888
DOI: 10.1097/01.hs9.0000566308.21128.18
Summary
Background: With the advent of tyrosine kinase inhibitors (TKIs), patients with chronic myeloid leukemia (CML) have a life expectancy similar to those of age‐ and sex‐matched healthy population. Nevertheless, patients receiving TKIs report chronic adverse events, some of which may be associated with severe symptoms including fatigue, edema, muscle cramps. Additionally, generic imatinib has license in various countries. In retrospective analyses and post‐marketing safety monitorization, it seems to have a similar efficacy and safety profile. However, quality of life and symptom burden issues in patients receiving TKIs still remains to be elucidated Aims: We aimed to assess the quality of life and symptom burden in patients receiving original imatinib, generic imatinib, dasatinib, and nilotinib. Methods: A total of 121 patients with CML who have been receiving any TKI for at least three months was contacted either by phone or at their routine outpatient clinic visits. All patients accepted to be included in the study. Their demographic data were recruited from chart files. Quality of life was assessed by EORTC‐QLQ‐C30 and its CML24 module. Symptom burden was assessed by MD Anderson Symptom Inventory (MDASI). Questionnaire scores were calculated per associated protocols. Group comparisons were made by Kruskal Wallis test. Results: Median age of patient population was 53 (28‐90) years. Fifty‐four (44.6%) was female. Eighty‐three patients (81.4%) had Sokal low‐intermediate disease. Most of the patients had good ECOG performance status (<2: 96%) and low hematopoietic cell transplantation‐comorbidity index score (<3: 90.8%). Median duration of TKIs was 31 (3‐154) months. Ninety‐eight patients (86.7%) had major molecular response at the time of questionnaire. Patients receiving different TKIs had comparable quality of life and treatment‐related symptom burden scores (table and figure). Summary/Conclusion: First and second generation TKIs as well as generic imatinib have similar impact on quality of life. Although these molecules have different safety profiles, severity of treatment‐related adverse events are generally mild. image